BR112014000380A2 - composição farmacêutica, métodos para tratamento e usos dos mesmos - Google Patents

composição farmacêutica, métodos para tratamento e usos dos mesmos

Info

Publication number
BR112014000380A2
BR112014000380A2 BR112014000380A BR112014000380A BR112014000380A2 BR 112014000380 A2 BR112014000380 A2 BR 112014000380A2 BR 112014000380 A BR112014000380 A BR 112014000380A BR 112014000380 A BR112014000380 A BR 112014000380A BR 112014000380 A2 BR112014000380 A2 BR 112014000380A2
Authority
BR
Brazil
Prior art keywords
treatment
methods
pharmaceutical composition
sglt
complications
Prior art date
Application number
BR112014000380A
Other languages
English (en)
Inventor
Luippold Gerd
Von Eynatten Maximilian
Johansen Odd-Erik
Klein Thomas
Broedl Uli
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46420221&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014000380(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112014000380A2 publication Critical patent/BR112014000380A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo patente de invenção: "composição farmacêutica, métodos para tratamento e usos dos mesmos". a presente invenção refere-se ao tratamento ou prevenção de prejuízo ou complicações renais usando um inibidor de sglt-2, por exemplo, em pacientes diagnosticados com distúrbios metabólicos e condições relacionadas.
BR112014000380A 2011-07-08 2012-07-03 composição farmacêutica, métodos para tratamento e usos dos mesmos BR112014000380A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161505598P 2011-07-08 2011-07-08
PCT/EP2012/062922 WO2013007557A1 (en) 2011-07-08 2012-07-03 Pharmaceutical composition, methods for treating and uses thereof

Publications (1)

Publication Number Publication Date
BR112014000380A2 true BR112014000380A2 (pt) 2017-02-14

Family

ID=46420221

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000380A BR112014000380A2 (pt) 2011-07-08 2012-07-03 composição farmacêutica, métodos para tratamento e usos dos mesmos

Country Status (22)

Country Link
US (5) US20130035298A1 (pt)
EP (2) EP3854404A1 (pt)
JP (2) JP2014520778A (pt)
KR (1) KR20140041697A (pt)
CN (2) CN106692126A (pt)
AR (1) AR087729A1 (pt)
AU (1) AU2012283229B2 (pt)
BR (1) BR112014000380A2 (pt)
CA (1) CA2837787C (pt)
CY (1) CY1124307T1 (pt)
DK (1) DK2729151T3 (pt)
EA (1) EA025497B1 (pt)
ES (1) ES2871904T3 (pt)
HR (1) HRP20210978T1 (pt)
HU (1) HUE054621T2 (pt)
LT (1) LT2729151T (pt)
MX (1) MX2014000010A (pt)
PL (1) PL2729151T3 (pt)
PT (1) PT2729151T (pt)
RS (1) RS61827B1 (pt)
SI (1) SI2729151T1 (pt)
WO (1) WO2013007557A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
JP5758900B2 (ja) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN113181161A (zh) * 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
PL3485890T3 (pl) * 2014-01-23 2023-08-28 Boehringer Ingelheim Vetmedica Gmbh Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
US10350311B2 (en) 2014-03-04 2019-07-16 Otsuka Pharmaceutical Co., Ltd. Iohexol powder and method of using the same
US20170319539A1 (en) * 2014-10-01 2017-11-09 Mylan Laboratories Ltd. Amorphous Empagliflozin
CN107223052A (zh) * 2015-03-27 2017-09-29 豪夫迈·罗氏有限公司 包含sembragiline的药物制剂
KR20230028568A (ko) * 2016-03-16 2023-02-28 베링거 인겔하임 인터내셔날 게엠베하 엠파글리플로진을 포함하는 약제학적 조성물 및 이의 용도
CN109922813A (zh) * 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
WO2020089761A1 (en) * 2018-11-01 2020-05-07 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising of remogliflozin or salt or ester thereof and vildagliptin or salt thereof
US11655240B1 (en) * 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
RS52365B (en) 2004-03-16 2012-12-31 Boehringer Ingelheim International Gmbh BENZOL DERIVATIVES SUBSTITUTED BY GLUCOPYRANOSIL, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, THEIR USE AND THE PROCEDURE FOR THEIR PRODUCTION
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
ATE407938T1 (de) 2004-12-16 2008-09-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2006124529A1 (en) 2005-05-13 2006-11-23 Eli Lilly And Company Glp-1 pegylated compounds
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
BRPI0615882A2 (pt) 2005-09-08 2011-05-31 Boehringer Ingelheim Int formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP2054426A1 (en) 2006-08-15 2009-05-06 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
WO2008049923A1 (en) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
JP2010508371A (ja) 2006-11-06 2010-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
EA018495B1 (ru) 2006-11-09 2013-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
WO2009020802A2 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
BRPI1013640A2 (pt) * 2009-02-13 2019-09-24 Boehringer Ingelheim Int composicao farmaceutica, metodos para o tratamento e usos dos mesmos
JP5758900B2 (ja) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
NZ598318A (en) 2009-09-30 2014-02-28 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof

Also Published As

Publication number Publication date
CN103732230A (zh) 2014-04-16
RS61827B1 (sr) 2021-06-30
US20230405032A1 (en) 2023-12-21
LT2729151T (lt) 2021-05-25
AU2012283229A1 (en) 2014-01-09
EP2729151A1 (en) 2014-05-14
EP3854404A1 (en) 2021-07-28
JP2016121156A (ja) 2016-07-07
US20180214468A1 (en) 2018-08-02
MX2014000010A (es) 2014-02-27
ES2871904T3 (es) 2021-11-02
CA2837787A1 (en) 2013-01-17
EP2729151B1 (en) 2021-03-31
NZ618546A (en) 2016-02-26
CN106692126A (zh) 2017-05-24
PL2729151T3 (pl) 2021-10-18
EA025497B1 (ru) 2016-12-30
PT2729151T (pt) 2021-05-25
AU2012283229B2 (en) 2017-06-15
US20200268777A1 (en) 2020-08-27
SI2729151T1 (sl) 2021-06-30
WO2013007557A1 (en) 2013-01-17
EA201400119A1 (ru) 2014-08-29
HRP20210978T1 (hr) 2021-09-17
AR087729A1 (es) 2014-04-16
KR20140041697A (ko) 2014-04-04
HUE054621T2 (hu) 2021-09-28
CY1124307T1 (el) 2022-07-22
US20130035298A1 (en) 2013-02-07
CA2837787C (en) 2021-09-14
JP2014520778A (ja) 2014-08-25
US20220096505A1 (en) 2022-03-31
DK2729151T3 (da) 2021-06-28

Similar Documents

Publication Publication Date Title
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
BR112013031032A2 (pt) inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
PH12015502275B1 (en) Therapuetic uses of empagliflozin
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
BR112012032778A2 (pt) "proteínas multiespecíficas e multivalentes"
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
BR112012008282A2 (pt) anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
BR112014007257A2 (pt) composto, medicamento, métodos para inibir um colesterol 24-hidrolase em um mamífero e para a profilaxia ou tratamento de doença neurodegenerativa em um mamífero, e, uso do composto ou sal
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
BR112015017775A2 (pt) enzima cistationina beta-sintase para o tratamento de homocistinúria
BRPI0908541B8 (pt) uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas
BR112014024308A8 (pt) uso de neuregulina para tratar lesão de nervo periférico
BR112014012746A8 (pt) nanoveículos de diagnóstico e/ou terapêutica direcionada por mmp
BR112012008310A2 (pt) métodos para tratamento de tumores cerebrais

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]